Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient
Rodríguez-Jiménez P, Mir-Viladrich I, Chicharro P, Solano-López G, López-Longo FJ, Taxonera C, Sánchez-Martínez P, Martínez-Lacasa X, et al. (13 authors)
Actas dermo-sifiliograficas · 2018-06
Abstract
Patients with chronic inflammatory diseases being treated with immunosuppressive drugs, and with tumor necrosis factor inhibitors in particular, have an increased risk of infection by Mycobacterium tuberculosis. Screening for latent tuberculosis infection and preventive therapy to reduce the risk of progression to active tuberculosis are mandatory in this group of patients. This updated multidisciplinary consensus document presents the latest expert opinions on the treatment and prevention of tuberculosis in candidates for biologic therapy and establishes recommendations based on current knowledge relating to the use of biologic agents.
MeSH terms
- T-Lymphocyte Subsets
- Humans
- Tuberculosis
- Hidradenitis Suppurativa
- Psoriasis
- Tumor Necrosis Factor-alpha
- Antibodies, Monoclonal
- Antitubercular Agents
- Drug Monitoring
- Biological Therapy
- Risk
- Immunity, Cellular
- Patient Selection
- Latent Tuberculosis